Primer sets, kits and systems for rapid diagnosis of FSHD
Through PCR combined with NGS high-throughput sequencing technology, the methylation level of D4Z4 repeat sequence in 4q35 region of FSHD patients was determined, which solved the complex and cost problems of existing FSHD diagnosis methods, and achieved rapid and accurate diagnosis of FSHD, which was suitable for clinical applications. .
Patent Information
- Application Number
- CN202411087702.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-09
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-08-09
AI Technical Summary
The existing FSHD diagnostic methods are complex in operation, costly and have low detection accuracy, especially for the distinction between FSHD1 and FSHD2 and the rapid diagnosis.
Using PCR combined with NGS high-throughput sequencing technology, the methylation level of the D4Z4 repeat sequence in the 4q35 region is determined by designing specific primers to achieve rapid molecular diagnosis of FSHD, which is convenient to operate, low cost and high accuracy.
It achieves accurate distinction between FSHD patients and normal patients, has high sensitivity and good accuracy in the test results, is suitable for clinical promotion and application, simplifies the diagnosis process and reduces costs.
Smart Images

Figure SMS_1 
Figure SMS_2
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical detection, and in particular relates to a primer set, a kit and a system for rapid diagnosis of facioscapulohumeral muscular dystrophy (FSHD). Background Art
[0002] Facioscapulohumeral muscular dystrophy (FSHD) is a hereditary muscle disease. The inheritance pattern of FSHD is complex, mainly autosomal dominant inheritance. Most patients are familial, and a few are sporadic. The pathogenesis of FSHD is related to genetic variations in the chromosome 4q35 region. According to the different genetic variations, FSHD is divided into two types: FSHD1 and FSHD2; FSHD1 is caused by the deletion of repeat units in the D4Z4 region of the long arm of chromosome 4q, accounting for about 95% of all FSHD cases; while FSHD2 is caused by the mechanism of non-D4Z4 region repeat unit deletion, but FSHD1 and FSHD2 are difficult to distinguish in clinical symptoms. Both will show atrophy and weakness of the face, shoulder girdle and upper arm muscles, and the progression rate and severity of the disease vary greatly among patients. The epigenetic mechanism of FSHD1 and FSHD2 is the same, both of which are caused by the obstruction of methylation in the D4Z4 region, which leads to the epigenetic de-repression of the normally silent gene DUX4. Both FSHD1 and FSHD2 patients have epigenetic changes such as hypomethylation of the CpG island of the D4Z4 repeat sequence and the loss of histone inhibitory modification. Currently, the diagnosis of FSHD relies on the combination of clinical manifestations and molecular diagnostic methods, among which molecular diagnostic methods mainly include Southern blot analysis, PCR, gene sequencing and epigenetic analysis.
[0003] Technical defects and shortcomings of existing diagnostic methods:
[0004] Among the current molecular diagnostic methods, Southern blot analysis is considered the gold standard method for diagnosing FSHD1. It is used to detect the shortening of the D4Z4 repeat sequence in the 4q35 region, but the detection operation of this technology is difficult and has high requirements for instruments, environment, and personnel. The PCR method can be used for preliminary screening of the shortening of the D4Z4 repeat sequence, but it cannot accurately determine the copy number of the repeat sequence, and the detection accuracy is not as good as Southern blot analysis. Gene sequencing is used to detect mutations in the SMCHD1 or DNMT3B genes in FSHD2. Known and unknown mutations of these genes can be identified through whole exome sequencing (WES) or targeted sequencing, but this technology requires the design of probes in the corresponding regions for hybridization capture, which is complex and costly.
[0005] Currently, detecting the methylation status of the D4Z4 region through epigenetic analysis can help to achieve rapid diagnosis of FSHD patients. Currently, there are no reports on the use of PCR combined with NGS high-throughput sequencing to detect the methylation level of the chromosome 4q35 D4Z4 region for FSHD diagnosis. Summary of the invention
[0006] In order to overcome the shortcomings and deficiencies of the prior art, the object of the present invention is to provide a primer set, a kit and a system for rapid diagnosis of FSHD.
[0007] The present invention provides a molecular biological detection method for rapid diagnosis of facioscapulohumeral muscular dystrophy (FSHD). The method can accurately distinguish FSHD positive patients from normal patients by measuring the gene methylation level of the D4Z4 region of the long arm 4q35 of human chromosome 4. The method uses PCR combined with NGS high-throughput sequencing technology, is easy to operate, low in price, high in accuracy, and suitable for popularization and application.
[0008] The purpose of the present invention is achieved through the following technical solutions:
[0009] The present invention designs four specific primers based on the D4Z4 repeat sequence in the 4q35 region of the human genome, which are used to amplify the 4qA haplotype after genomic DNA methylation conversion. The 4qA gene PCR product is constructed into an NGS library and NGS sequencing is performed to analyze the methylation level of the 4qA gene, thereby realizing rapid molecular diagnosis of FSHD based on the epigenetic methylation ratio of the 4qA gene.
[0010] In a first aspect, the present invention provides a primer set for rapid diagnosis of FSHD, wherein the primer set comprises the following primers:
[0011] Specific primers for 4qA haplotype include:
[0012] External primer 1: 5′-GGAAGAATATYGGGTTTTGTTGG-3′ (SEQ ID No. 1);
[0013] External primer 2: 5′-CAACRAACTCCCTTACACRTCAA-3′ (SEQ ID No. 2);
[0014] Internal primer 1: 5′-TTTGGGTTGTGGGAGTAGTT-3′ (SEQ ID No. 3);
[0015] Internal primer 2: 5′-AACTCCRCRCTAACAACTAAAA-3′ (SEQ ID No. 4).
[0016] The second aspect of the present invention provides use of the primer set described in the first aspect in preparing a kit for rapid diagnosis of FSHD.
[0017] In one embodiment, the method for rapid diagnosis of FSHD comprises the following steps:
[0018] (1) Provide genomic DNA to be tested;
[0019] (2) performing methylation conversion on the genomic DNA to be detected in step (1) to obtain converted genomic DNA;
[0020] (3) using the transformed genomic DNA of step (2) as a template, performing nested PCR amplification using the primer set according to the first aspect;
[0021] (4) Construction of NGS library;
[0022] (5) Perform NGS library sequencing and analyze the Q1-quartile methylation ratio of the 4qA gene and interpret the results.
[0023] In one embodiment, the nested PCR amplification product can be further purified before the next reaction; the purification is performed using DNA purification magnetic beads.
[0024] In a third aspect, the present invention provides a kit for rapid diagnosis of FSHD, comprising the primer set described in the first aspect.
[0025] The kit also includes DNA polymerase, reaction buffer and the like.
[0026] In a fourth aspect, the present invention provides a device for rapid diagnosis of FSHD, comprising: the kit described in the third aspect; and a kit for constructing an NGS library.
[0027] In one embodiment, the kit for constructing an NGS library includes an end repair enzyme, a linker, a ligase, DNA purification magnetic beads, a library PCR primer, and a library PCR reaction buffer.
[0028] In a fifth aspect, the present invention provides a method for rapid diagnosis of FSHD, comprising the following steps:
[0029] (1) Provide genomic DNA to be tested;
[0030] (2) performing methylation conversion on the genomic DNA to be detected in step (1) to obtain converted genomic DNA;
[0031] (3) using the transformed genomic DNA of step (2) as a template, performing nested PCR amplification using the primer set according to the first aspect;
[0032] (4) Construction of NGS library;
[0033] (5) Perform NGS library sequencing and analyze the Q1-quartile methylation ratio of the 4qA gene and interpret the results.
[0034] In one embodiment, the genomic DNA is genomic DNA from at least one of a whole blood sample, a saliva sample, and a cultured cell sample, and preferably a commercial DNA extraction kit can be used.
[0035] In one embodiment, the methylation conversion is a methylation enzymatic conversion; preferably, a commercial enzyme conversion kit can be used.
[0036] In one embodiment, the nested PCR amplification product can be further purified before the next reaction; the purification is performed using DNA purification magnetic beads.
[0037] In one embodiment, the construction of the NGS library can be carried out using a commercial NGS library preparation kit.
[0038] In one embodiment, the NGS library sequencing is performed using a second-generation high-throughput sequencer; different sequencing platforms can be adapted according to the type of NGS library, and the amount of sequencing data for each sample 4qA gene library is 0.5G.
[0039] In one embodiment, the results are interpreted and the results are comprehensively determined based on the results of the Q1-quartile methylation ratio of the 4qA gene:
[0040] Samples with a Q1-quartile methylation ratio of 4qA gene ≤15% were FSHD-positive, and samples with a Q1-quartile methylation ratio of 4qA gene greater than 15% were FSHD-negative.
[0041] In a sixth aspect, the present invention provides a system for rapid diagnosis of FSHD, comprising the following modules:
[0042] (a) a collection module, which is used to provide genomic DNA to be detected;
[0043] (b) a methylation conversion module, which is used to perform methylation conversion on the genomic DNA to be detected in module (a) to obtain converted genomic DNA;
[0044] (c) an amplification module, which is used to perform nested PCR amplification using the transformed genomic DNA of module (b) as a template and the primer set according to the first aspect;
[0045] (d) a library construction module, which is used to construct an NGS library;
[0046] (e) Sequencing analysis module, which is used for NGS library sequencing and analysis of the Q1-quartile methylation ratio of the 4qA gene and interpretation of the results.
[0047] In one embodiment, in the collection module, the genomic DNA is genomic DNA of at least one of a whole blood sample, a saliva sample, and a cultured cell sample, and preferably a commercial DNA extraction kit can be used.
[0048] In one embodiment, the methylation conversion module converts methylation into methylase conversion; preferably, a commercial enzyme conversion kit can be used.
[0049] In one embodiment, the amplification module comprises the kit according to the third aspect.
[0050] In one embodiment, the reaction system of the first round of nested PCR amplification in the amplification module is a 20 μL reaction system: 2.0 μL of 10×PCR buffer, 3.2 μL of dNTP mixture, 0.2 μL of DNA polymerase, 3.2 μL of outer primer 1 and outer primer 2, 2 μL of template DNA, and the mixture is filled to 20 μL with sterile deionized water;
[0051] The reaction system for the second round of nested PCR amplification was a 20 μL reaction system: 2.0 μL of 10× PCR buffer, 3.2 μL of dNTP mixture, 0.2 μL of DNA polymerase, 3.2 μL each of inner primer 1 and inner primer 2, and 2 μL of the first round PCR product, which was made up to 20 μL with sterile deionized water;
[0052] Among them, 10× PCR buffer is added with Mg 2+ 10× PCR buffer, Mg 2+ The concentration is 25mM; in the dNTP mixture, the concentration of each dNTP is 2.5mM; the concentration of DNA polymerase is 5U / μL, and the preservation solution includes the following components: 20mM Tris-HCl (PH8.0), 100mM potassium chloride, 0.1mM EDTA, 1mM DTT, 0.5% Tween-20, 0.5% NP-40, 50% glycerol, the concentrations of outer primer 1 and outer primer 2 are both 2.5μmol / L; the concentrations of inner primer 1 and inner primer 2 are both 1.25μmol / L.
[0053] In one embodiment, the reaction procedures of the amplification module and the nested PCR amplification are: 95°C 3min, 95°C 30sec, 62°C 30sec (-0.5°C / cycle), 72°C 1min, 10cycles; 95°C 30sec, 57°C 30sec, 72°C 1min, 20 cycles; 72°C 5 min, 4°C hold.
[0054] In one embodiment, the amplification module and the nested PCR amplification product can be further purified before the next reaction; the purification is performed using DNA purification magnetic beads.
[0055] In one embodiment, the library construction module includes reagents for constructing an NGS library, and the reagents for constructing an NGS library include adapters, ligases, DNA purification magnetic beads, library PCR primers, and library PCR reaction buffer.
[0056] In one embodiment, the NGS library sequencing is performed using a second-generation high-throughput sequencer; different sequencing platforms can be adapted according to the type of NGS library, and the amount of sequencing data for each sample 4qA gene library is 0.5G.
[0057] In one embodiment, after performing NGS library sequencing and analyzing the Q1-quartile methylation ratio of the 4qA gene through a sequencing analysis module, the results are interpreted:
[0058] Samples with a Q1-quartile methylation ratio of 4qA gene ≤15% were FSHD-positive, and samples with a Q1-quartile methylation ratio of 4qA gene greater than 15% were FSHD-negative.
[0059] Compared with the prior art, the present invention has the following advantages and effects:
[0060] The present invention is used for rapid molecular diagnosis of facioscapulohumeral muscular dystrophy (FSHD), and the method is easy to operate, low in detection cost, and has high sensitivity and accuracy in detection results, which is suitable for clinical promotion and application. The present invention detects the methylation level of the 4qA haplotype of the D4Z4 repeat sequence in the 4q35 region based on the PCR+NGS high-throughput sequencing method, enriches the target gene by PCR, does not require complex probe capture sequencing, is easy to operate and has low cost; adopts high-throughput sequencing technology, has high sensitivity and accuracy in detection results, and is suitable for clinical rapid diagnosis applications. DETAILED DESCRIPTION
[0061] The present invention is further described in detail below in conjunction with examples, but the embodiments of the present invention are not limited thereto. The materials involved in the following examples can be obtained from commercial channels unless otherwise specified. The methods described are conventional methods unless otherwise specified.
[0062] In the embodiments of the present invention, the amplification primers (SEQ ID No. 1-SEQ ID No. 4) of the 4qA gene were synthesized by Guangzhou Aiji Biotechnology Co., Ltd. The genomic DNA methylation enzymatic conversion reagent EpiArt DNA Enzymatic Methylation Kit (EM301) was purchased from Nanjing Novogene Biotechnology Co., Ltd. NGS library preparation reagents and magnetic bead purification reagents were purchased from Jiajian (Guangzhou) Bioengineering Technology Co., Ltd. The NGS library was sent to Beijing Geneplus Technology Co., Ltd. for high-throughput sequencing.
[0063] Example 1
[0064] This embodiment is an experimental operation method for epigenetic molecular diagnosis of facioscapulohumeral muscular dystrophy (FSHD).
[0065] 1. Extraction of sample genomic DNA:
[0066] Whole blood samples were collected from subjects with facioscapulohumeral muscular dystrophy (FSHD) of different etiologies and normal subjects, and genomic DNA was extracted using a commercial kit. The extracted DNA was stored at -20°C and stored at -80°C for long-term storage.
[0067] 2. Genomic DNA methylation conversion
[0068] Refer to the instructions of EpiArt DNA Enzymatic Methylation Kit (EM301) for genomic DNA methylation enzymatic conversion, and use 100ng genomic DNA input for enzymatic methylation DNA conversion. Unmethylated cytosine on the genome is converted into uracil. The methylated single-stranded DNA is stored at -20℃, and stored at -80℃ for long-term storage.
[0069] 3. PCR Amplification
[0070] Using the methylated genomic DNA as a template, 4qA gene outer primer 1 and outer primer 2 (SEQ ID No. 1-SEQ ID No. 2) were used for the first round of PCR amplification, and the reaction system was prepared according to the following PCR amplification system:
[0071] Components volume 10×PCR buffer dNTP mix 2.0 μL3.2 μL DNA polymerase 0.2 μL Outer Primer 1 (2.5 µM) 3.2 μL Outer Primer 2 (2.5 µM) 3.2 μL DNA (2~10ng) 2.0 μL <![CDATA[ddH2O]]> 6.2 μL Total 20.0 μL
[0072] Among them, 10× PCR buffer is added with Mg2+ 10× PCR buffer, Mg 2+ The concentration is 25mM; in the dNTP mixture, the concentration of each dNTP is 2.5mM; the concentration of DNA polymerase is 5U / μL, and the preservation solution includes the following components: 20mM Tris-HCl (pH8.0), 100mM potassium chloride, 0.1mM EDTA, 1mM DTT, 0.5% Tween-20, 0.5% NP-40, and 50% glycerol.
[0073] Mix the prepared reaction system, centrifuge briefly, transfer to a PCR instrument, and amplify according to the following PCR reaction program:
[0074]
[0075] The size of the first-round PCR product of the 4qA gene was 679 bp. The second-round PCR amplification was performed using the first-round PCR product as a template. The amplification primers were 4qA gene internal primer 1 and internal primer 2 (SEQ ID No.3-SEQ ID No.4), and the template amount was 10% of the first-round PCR product amount. The second-round PCR reaction system was prepared according to the following amplification system:
[0076] Components volume 10×PCR buffer dNTP mix 2.0 μL3.2 μL DNA polymerase 0.2 μL Inner Primer 1 (1.25 µM) 3.2 μL Inner Primer 2 (1.25µM) 3.2 μL First round PCR products 2.0 μL <![CDATA[ddH2O]]> 6.2 μL Total 20.0 μL
[0077] The prepared reaction system was mixed, centrifuged briefly, and transferred to a PCR instrument for reaction. The second round of PCR amplification procedure was the same as the first round of PCR.
[0078] After the second round of PCR, 2 μL of PCR product was taken from each sample and tested by 1.5% agarose gel electrophoresis (180V, 17min), confirming that the fragment size was 269bp. The PCR amplification product does not need to be fragmented by enzyme digestion / ultrasonic interruption, and can be directly used for NGS library preparation. Then PCR product purification was performed according to the following steps:
[0079] (1) Take out the purified magnetic beads 30 minutes in advance and place them at room temperature. Vortex and mix thoroughly before use.
[0080] (2) Add 30 μL of purified magnetic beads (1.5×) to the amplified product tube, incubate at room temperature for 5 min, then centrifuge briefly. Place the PCR tube on a magnetic rack until the solution becomes clear.
[0081] (3) Discard the supernatant, add 200 μL 80% ethanol, and let stand for 30 seconds;
[0082] (4) Discard the supernatant, add 200 μL 80% ethanol, and let stand for 30 seconds;
[0083] (5) Carefully discard the supernatant and absorb as much ethanol as possible, but be careful not to absorb the magnetic beads at the bottom;
[0084] (6) Keep the PCR tube on the magnetic rack at all times, open the lid and air-dry the magnetic beads for 5-10 min until the surface of the beads is non-reflective and free of cracks (be careful not to over-dry, otherwise it will cause DNA loss);
[0085] (7) Add 22 μL of ddH2O and mix by pipetting. Incubate at room temperature for 5 min. Place on a magnetic rack (about 2 min) until the solution becomes clear. Carefully transfer 20 μL of the supernatant to a new tube (do not touch the magnetic beads).
[0086] The concentration of each purified PCR product was measured using a Qubit 4.0 fluorometer. The purified PCR product can be stored stably at 4°C for one week. For long-term storage, place it at -20°C and avoid repeated freezing and thawing.
[0087] 4. NGS Library Preparation
[0088] 4.1 End repair
[0089] Determine the concentration of the PCR purified product, take 100 ng of each sample and add water to 50 μL, and add End Prep Mix 4 to each tube for end repair according to the following requirements.
[0090] Components volume End Prep Mix 4 15 μL DNA 50 μL Total Volume 65 μL
[0091] Use a pipette to gently pipette to mix (do not oscillate to mix), and centrifuge briefly; incubate in a PCR instrument: heat cover at 105°C.
[0092] Temp Duration 20℃ 15 min 65℃ 15 min 4℃ Hold
[0093] 4.2 Connector connection
[0094] Add the following Adapter Ligation Reaction Solution to each End Preparation product:
[0095] Components volume Rapid Ligation Buffer 2 25 μL Rapid DNA Ligase 5 μL DNA Adapter X 5 μL / piece End repair products 65 μL Total Volume 100 μL
[0096] Use a pipette to gently mix (do not oscillate), centrifuge briefly, and incubate in a PCR instrument: heat cover at 50°C.
[0097] Temp Duration 20℃ 15 min 4℃ Hold
[0098] 4.3 Purification of ligation product
[0099] Follow the steps below to purify the ligation product:
[0100] (1) Take out the purified magnetic beads 30 minutes in advance and place them at room temperature. Vortex and mix thoroughly before use.
[0101] (2) Add 60 μL of purified magnetic beads to the amplified product tube, incubate at room temperature for 5 min, then centrifuge briefly. Place the PCR tube on a magnetic rack until the solution becomes clear.
[0102] (3) Discard the supernatant, add 200 μL 80% ethanol, and let stand for 30 seconds;
[0103] (4) Discard the supernatant, add 200 μL 80% ethanol, and let stand for 30 seconds;
[0104] (5) Carefully discard the supernatant and absorb as much ethanol as possible, but be careful not to absorb the magnetic beads at the bottom;
[0105] (6) Keep the PCR tube on the magnetic rack at all times, open the lid and air-dry the magnetic beads for 5-10 min until the surface of the beads is non-reflective and free of cracks (be careful not to over-dry, otherwise it will cause DNA loss);
[0106] (7) Add 22 μL of ddH2O and mix by pipetting. Incubate at room temperature for 5 min. Place on a magnetic rack (about 2 min) until the solution becomes clear. Carefully transfer 20 μL of the supernatant to a new tube (do not touch the magnetic beads).
[0107] Note: The samples can be stored stably at 4°C for one week. For long-term storage, place at -20°C and avoid repeated freezing and thawing.
[0108] 4.4 Library PCR amplification
[0109] Set up the PCR system and mix according to the following standards:
[0110] Reagents volume VAHTS HiFi Amplification Mix 25 μL PCR Primer Mix for MGI 5 μL Purified linker product 20 μL Total Volume 50 μL
[0111] Use a pipette to mix gently (do not oscillate), centrifuge briefly, and run the following program on the PCR instrument: heat the lid at 105°C.
[0112]
[0113] 4.5 Library PCR product purification
[0114] (1) Take out the purified magnetic beads 30 minutes in advance and place them at room temperature. Vortex and mix thoroughly before use.
[0115] (2) Add 45 μL of purified magnetic beads (0.9X) to the amplified product tube, incubate at room temperature for 5 min, then centrifuge briefly. Place the PCR tube on a magnetic rack until the solution becomes clear.
[0116] (3) Discard the supernatant, add 200 μL 80% ethanol, and let stand for 30 seconds;
[0117] (4) Discard the supernatant, add 200 μL 80% ethanol, and let stand for 30 seconds;
[0118] (5) Carefully discard the supernatant and absorb as much ethanol as possible, but be careful not to absorb the magnetic beads at the bottom;
[0119] (6) Keep the PCR tube on the magnetic rack at all times, open the lid and air-dry the magnetic beads for 5-10 min until the surface of the beads is non-reflective and free of cracks (be careful not to over-dry, otherwise it will cause DNA loss);
[0120] (7) Add 22 μL of ddH2O and mix by pipetting. Incubate at room temperature for 5 min. Place on a magnetic rack (about 2 min) until the solution becomes clear. Carefully transfer 20 μL of the supernatant to a new tube (do not touch the magnetic beads).
[0121] Note: The samples can be stored stably at 4°C for one week. For long-term storage, place at -20°C and avoid repeated freezing and thawing.
[0122] 4.6 Library product quality inspection
[0123] The purified library product was subjected to 1.5% agarose gel electrophoresis and the Qubit instrument to determine the size and concentration of the amplified DNA fragment. The size of the amplified DNA fragment should be between 300bp and 500bp, and the next step of the experiment can be continued.
[0124] 5. NGS library sequencing
[0125] The constructed NGS library was sent to Beijing Geneplus Technology Co., Ltd. for BGI DNBSEQ-T7 high-throughput sequencing (NGS library circularization and DNB preparation were prepared by the sequencing service provider). The amount of sequencing data for each sample 4qA gene library was 0.5G.
[0126] 6. Data Analysis of Sequencing Results
[0127] The results of read1 and read2 of NGS sequencing data were spliced according to the sequence ID, and the spliced sequences were compared for sequence homology similarity. Sequence results with homology similarity ≥ 85% were retained. The methylation software QUMA was used to analyze the sequence methylation conversion efficiency, and the sequencing result sequences with methylation conversion efficiency ≥ 95% and homology similarity ≥ 95% were retained. According to the matching of methylation sites in the reference genome sequence, the Excel QUARTILE function was used to statistically calculate the Q1-quartile of the methylation ratio of the 4qA gene of each sample, and the FSHD result of each sample was interpreted according to the positive result judgment criteria.
[0128] Positive result interpretation criteria: If the Q1-quartile methylation ratio of the 4qA gene of the sample is ≤15%, it is FSHD positive; if the Q1-quartile methylation ratio of the 4qA gene of the sample is >15%, it is FSHD negative.
[0129] Example 2
[0130] This embodiment is a clinical sample detection of an epigenetic molecular diagnostic method for facioscapulohumeral muscular dystrophy (FSHD).
[0131] A total of 9 suspected FSHD clinical samples and 10 normal clinical samples were collected, and FSHD epigenetic PCR+NGS detection and analysis were performed according to the detection method flow in Example 1. As a result, 9 of the 19 samples were positive for FSHD, and the other 10 samples were negative for FSHD. The specific test results are shown in the table below. The test results were further compared with the clinical test results of the samples, and the test result consistency rate was 100%.
[0132] Sample No. Sample Type Sample status (clinical test results) 4qA gene methylation ratio (Q1-quartile) FSHD test results 1 Whole blood FSHD1 3.2% Positive 2 Whole blood FSHD1 6.5% Positive 3 Whole blood FSHD1 3.2% Positive 4 Whole blood FSHD1 3.2% Positive 5 Whole blood FSHD1 6.5% Positive 6 Whole blood FSHD1 3.2% Positive 7 Whole blood FSHD1 6.5% Positive 8 Whole blood FSHD1 3.2% Positive 9 Whole blood FSHD2 6.5% Positive 10 Whole blood Negative 30.0% Negative 11 Whole blood Negative 44.7% Negative 12 Whole blood Negative 67.7% Negative 13 Whole blood Negative 48.4% Negative 14 Whole blood Negative 73.3% Negative 15 Whole blood Negative 63.3% Negative 16 Whole blood Negative 60.9% Negative 17 Whole blood Negative 61.3% Negative 18 Whole blood Negative 43.3% Negative 19 Whole blood Negative 35.5% Negative
[0133] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.
Claims
1. Use of a primer set in the preparation of a kit for rapid diagnosis of facioscapulohumeral muscular dystrophy, characterized in that: The primer set includes the following primers: Outer primer 1: 5′-GGAAGAATATYGGGTTTTGTTGG-3′; Outer primer 2: 5′-CAACRAACTCCCTTACACRTCAA-3′; Internal primer 1: 5′-TTTGGGTTGTGGGAGTAGTT-3′; Inner primer 2: 5′-AACTCCRCRCTAACAACTAAAA-3′.
2. The use according to claim 1, characterized in that: The method for rapid diagnosis of facioscapulohumeral muscular dystrophy comprises the following steps: (1) Provide genomic DNA to be tested; (2) performing methylation conversion on the genomic DNA to be detected in step (1) to obtain converted genomic DNA; (3) using the transformed genomic DNA of step (2) as a template, and performing nested PCR amplification using the primer set according to claim 1; (4) Construction of NGS library; (5) Perform NGS library sequencing and analyze the Q1-quartile methylation ratio of the 4qA gene and interpret the results.
3. The use according to claim 1, characterized in that: The kit also includes DNA polymerase and reaction buffer.
4. Use of the primer set according to claim 1 in preparing a device for rapid diagnosis of facioscapulohumeral muscular dystrophy, characterized in that: The device comprises the kit according to any one of claims 1 to 3 and a kit for constructing an NGS library.
5. The use according to claim 4, characterized in that: The kit for constructing an NGS library comprises an end repair enzyme, a linker, a ligase, DNA purification magnetic beads, a library PCR primer and a library PCR reaction buffer.
